Arcus Combo Improved Overall Survival in Non-Small Cell Lung Cancer

 

• Domvanalimab plus zimberelimab was associated with greater progression-free survival, overall survival, and objective response rate compared with those of zimberelimab or chemotherapy

• A 36% reduction in risk of death (HR=0.64) was observed for domvanalimab plus zimberelimab compared to zimberelimab alone; zimberelimab reached a median overall survival of two years while the median overall survival for domvanalimab plus zimberelimab was not reached

• Treatment-related adverse events leading to treatment discontinuation were low (10.5%) for the combination of domvanalimab and zimberelimab relative to chemotherapy (23.5%)

• Arcus will discuss these results on its earnings call at 2:00 PM PT / 5:00 PM ET Wednesday, November 6, 2024

https://www.businesswire.com/news/home/20241105383975/en